{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"77.8","value":"55.6"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"75.7","value":"15.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"321"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"description":"Time to Progression was defined as the time from the start of nilotinib to the earliest date of Disease Progression (PD), discontinuation due to PD or death.\n\nDisease progression was defined as an increase in the number of circulating leukemic cells via cytogenetic assessment using real-time quantitative reverse transcriptase polymerase chain reaction (PCR).","dispersionType":"Full Range","groups":[{"description":"Adult participants PH+ CML-CP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).","id":"OG000","title":"CML-CP With Prior Imatinib Only"},{"description":"Adult participants Ph+ CML-AP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).","id":"OG001","title":"CML-AP With Prior Imatinib Only"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS): All participants who received at least one dose of study medication.\n\nTime to progression was not an efficacy variable for participants who received the CML-CP with prior imatinib and other TKI (Group B E8).","reportingStatus":"POSTED","timeFrame":"Up to End of the Treatment (Approximately 7.5 years)","title":"Time to Progression (TTP) (Phase II)","type":"SECONDARY","unitOfMeasure":"Months"}